Chrysalin Side Effects: Safety Signals and Warnings
Chrysalin safety concerns are compound-specific. The main listed side effects are Well-tolerated in Phase 2 trials, Mild injection site discomfort, and No systemic coagulation effects observed. The main warning signals are Not yet FDA-approved; still in clinical development, Theoretical concern regarding thrombin receptor activation in patients with thrombotic tendencies, and Limited data in patients with impaired healing (diabetes, immunosuppression).
Direct Answer
Chrysalin (TP508) has Phase 2 human data in bone fracture healing showing accelerated radiographic healing, particularly in osteoporotic patients. The thrombin-receptor mechanism is scientifically distinct from other healing peptides. Phase 2 results are promising but Phase 3 data is not yet available. A credible but not yet fully validated healing compound.
- Evidence grade
- Level C
- Research status
- Phase 2
- Category
- Healing & Recovery
- Best for
- Bone fracture healing acceleration, osteoporotic fracture recovery, thrombin receptor agonism research
Reported Side Effects
- Well-tolerated in Phase 2 trials
- Mild injection site discomfort
- No systemic coagulation effects observed
- No significant adverse events reported in clinical studies
Warnings
- Not yet FDA-approved; still in clinical development
- Theoretical concern regarding thrombin receptor activation in patients with thrombotic tendencies
- Limited data in patients with impaired healing (diabetes, immunosuppression)
- Long-term safety profile not fully established
Known or Plausible Interactions
- Anticoagulants (theoretical interaction via thrombin receptor pathway, though no coagulation effects observed)
- NSAIDs (may impair bone healing and reduce TP508 efficacy)
- Bone morphogenetic proteins (potential complementary effects)
Regulatory Context
Chrysalin (TP508) is an investigational drug that has completed Phase 2 clinical trials. Not yet FDA-approved. Orphan drug designation has been explored for certain indications. Available only through clinical trials or research suppliers.
Evidence Snapshot
| Evidence grade | Level C |
|---|---|
| Research status | Phase 2 |
| Best supported outcomes | Bone Fracture Healing (Level C), Soft Tissue Wound Healing (Level D), and Spinal Fusion Enhancement (Level D) |
| Primary citation count | 2 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Chrysalin Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/chrysalin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.